ERAS 2.54 (+3.67%)
US29479A1088• Biotechnology• Biotechnology
Intro Numbers Peers
  1. Home
  2. /
  3. All Stocks
  4. /
  5. ERAS

Erasca (ERAS) Stock Highlights

2.54 | +3.67%
2024-12-21 04:44:20
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The companys pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers.

Statistics

Range Today
2.38 2.59
Volume Today 2.43M
Range 1 Year
1.64 3.45
Volume 1 Year 401.42M
Range 3 Year
1.51 16
Volume 3 Year 793.9M
Range 10 Year
1.51 24.47
Volume 10 Year 839.1M

Highlights

Market Capitalization 887.06M (small)
Floating Shares 215.95M
Current Price 2.54
Price To Earnings -3.32
Price To Book 1.9
Earnings Per Share -0.94
Payout Ratio 0%

Performance

Latest +3.67%
1 Month -8.3%
3 Months -13.61%
6 Months +24.51%
1 Year +28.93%
3 Years -82.65%
5 Years -84.03%
10 Years -84.03%

Benchmarks

Market Capitalization

0 / 368

Gross Profits

0 / 278

Total Revenue

0 / 300

Total Rank

0 / 368

Free Cashflow

0 / 352

Performance 5 years

0 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.